Sipuleucel-T is an autologous cellular immunotherapy designed to stimulate an immune response to prostate cancer that prolongs the overall survival of men with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer (CRPC).
The clinical development program and key efficacy, safety, and immune response findings from the phase III studies are presented. The integration of sipuleucel-T into the treatment paradigm of advanced prostate cancer and future directions for research are discussed.
Written by:
Frohlich MW. Are you the author?
Executive Vice President, Research & Development and Chief Medical Officer, Dendreon Corp, Seattle, WA.
Reference: Semin Oncol. 2012 Jun;39(3):245-52.
doi: 10.1053/j.seminoncol.2012.02.004
PubMed Abstract
PMID: 22595047
UroToday.com Prostate Cancer Section